Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial

Authors: Nagesh Kalakonda, Marie Maerevoet, Federica Cavallo, George Follows, André Goy, Joost S.P. Vermaat, Olivier Casasnovas, Nada Hamad, Josée M. Zijlstra, Sameer Bakhshi, Réda Bouabdallah, Sylvain Choquet, Ronit Gurion, Brian T. Hill, Ulrich Jaeger, Juan‐Manuel Sancho, Michael Schuster, Catherine Thiéblemont, Fátima De la Cruz, Miklós Egyed, Sourav Mishra, Fritz Offner, Theodoros P. Vassilakopoulos, Krzysztof Warzocha, Daniel McCarthy, Xiwen Ma, Kelly Corona, Jean-Richard Saint-Martin, Hua Chang, Yosef Landesman, Anita Joshi, Hongwei Wang, Jatin J. Shah, Sharon Shacham, Michael Kauffman, Éric Van Den Neste, Miguel Canales - The Lancet 2020 cited by 337